Trial · NCT02630992
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Distribution of Participants Receiving Formulation 1 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product | Amoxicillin-clavulanate Potassium | PDD reported | 10 | Participants | |
| The Distribution of Participants Receiving Formulation 1 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product | Amoxicillin-clavulanate Potassium | PDD not reported | 30 | Participants | |
| The Distribution of Participants Receiving Formulation 2 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product | Amoxicillin-clavulanate Potassium | PDD reported | 12 | Participants | |
| The Distribution of Participants Receiving Formulation 2 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product | Amoxicillin-clavulanate Potassium | PDD not reported | 60 | Participants | |
| The Distribution of Participants Receiving Formulation 1 for Whom Diaper Dermatitis Was Reported and Associated With Study Product | Amoxicillin-clavulanate Potassium | Diaper dermatitis reported | 10 | Participants | |
| The Distribution of Participants Receiving Formulation 1 for Whom Diaper Dermatitis Was Reported and Associated With Study Product | Amoxicillin-clavulanate Potassium | Diaper dermatitis not reported | 30 | Participants | |
| The Distribution of Participants Receiving Formulation 2 for Whom Diaper Dermatitis Was Reported and Associated With Study Product | Amoxicillin-clavulanate Potassium | Diaper dermatitis reported | 15 | Participants | |
| The Distribution of Participants Receiving Formulation 2 for Whom Diaper Dermatitis Was Reported and Associated With Study Product | Amoxicillin-clavulanate Potassium | Diaper dermatitis not reported | 57 | Participants | |
| The Distribution of Participants Receiving Formulation 1 Categorized as Treatment Failure (TF) at or Before the End-of-Treatment Visit | Amoxicillin-clavulanate Potassium | Treatment failure | 4 | Participants | |
| The Distribution of Participants Receiving Formulation 1 Categorized as Treatment Failure (TF) at or Before the End-of-Treatment Visit | Amoxicillin-clavulanate Potassium | Clinical success | 31 | Participants | |
| The Distribution of Participants Receiving Formulation 2 Categorized as Treatment Failure (TF) at or Before the End-of-Treatment Visit | Amoxicillin-clavulanate Potassium | Treatment failure | 8 | Participants | |
| The Distribution of Participants Receiving Formulation 2 Categorized as Treatment Failure (TF) at or Before the End-of-Treatment Visit | Amoxicillin-clavulanate Potassium | Clinical success | 56 | Participants | |
The Distribution of Participants Receiving Formulation 1 Demonstrating Resolution of Acute Otitis Media (AOM) and Substantial Improvement of Symptoms That Would Allow Discontinuing Therapy at the Day 7 Visit | Amoxicillin-clavulanate Potassium | Resolution of AOM and improvement of symptoms | 23 | Participants | |
The Distribution of Participants Receiving Formulation 1 Demonstrating Resolution of Acute Otitis Media (AOM) and Substantial Improvement of Symptoms That Would Allow Discontinuing Therapy at the Day 7 Visit | Amoxicillin-clavulanate Potassium | No resolution of AOM or no improvement of symptoms | 11 | Participants | |
The Distribution of Participants Receiving Formulation 2 Demonstrating Resolution of Acute Otitis Media (AOM) and Substantial Improvement of Symptoms That Would Allow Discontinuing Therapy at the Day 7 Visit | Amoxicillin-clavulanate Potassium | Resolution of AOM and improvement of symptoms | 31 | Participants | |
The Distribution of Participants Receiving Formulation 2 Demonstrating Resolution of Acute Otitis Media (AOM) and Substantial Improvement of Symptoms That Would Allow Discontinuing Therapy at the Day 7 Visit | Amoxicillin-clavulanate Potassium | No resolution of AOM or no improvement of symptoms | 31 | Participants | |
| The Mean Score Representing the Parent or Guardian's Level of Satisfaction With Therapy for Participants Receiving Formulation 1 | Amoxicillin-clavulanate Potassium | 4.69 | Standard Deviation 0.72 | units on a scale | |
| The Mean Score Representing the Parent or Guardian's Level of Satisfaction With Therapy for Participants Receiving Formulation 2 | Amoxicillin-clavulanate Potassium | 4.75 | Standard Deviation 0.76 | units on a scale | |
| Distribution of Population Plasma Concentration of Amoxicillin According to Time For Participants Receiving Formulation 1 | Amoxicillin-clavulanate Potassium | 0.5 hours (approximate) | 14.36 | Standard Deviation 10.07 | micrograms per milliliter (mcg/ml) |
| Distribution of Population Plasma Concentration of Amoxicillin According to Time For Participants Receiving Formulation 1 | Amoxicillin-clavulanate Potassium | 1.5 hours (approximate) | 15.3 | Standard Deviation 0 | micrograms per milliliter (mcg/ml) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02630992/results